Tag: Bristol

Bristol Myers: presents data for lung cancer

(CercleFinance.com) – The group announces that neoadjuvant Opdivo (nivolumab) combined with chemotherapy offers benefits to patients with resectable non-small cell lung cancer with three-year follow-up in the CheckMate -816 trial.…

Bristol Myers: Opdivo has been approved by the FDA

(CercleFinance.com) – Bristol Myers Squibb announced that Opdivo (nivolumab) has been approved by the United States Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients…

Bristol Myers: Presents new cancer data

(CercleFinance.com) – Bristol Myers Squibb today announced the presentation of data from more than 55 studies across its oncology portfolio in more than 10 tumors at the 2023 European Society…

Bristol Myers Squibb buys biotech Mirati

(AOF) – Bristol Myers Squibb announced the acquisition of the American biotech Mirati for $58.00 per share, representing a net value of $4.8 billion and up to $5.8 billion, while…

Bristol Myers: Positive data in lung cancer

Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where…

Bristol Myers: FDA approval in anemia

(CercleFinance.com) – Bristol Myers Squibb reports that the US FDA has approved Reblozyl as a first-line treatment for anemia in adults with low-risk myelodysplastic syndromes (MDS) who may require transfusions.…

Bristol Myers: new results for the HCM

(CercleFinance.com) – Bristol Myers Squibb announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic hypertrophic obstructive…